💊 Pfizer (PFE): Why a Former Vanguard CEO Just Bought Nearly $1 Million of This 6.4% Dividend Stock

Inside the $2 Million Insider Double-Signal, 8.6× Forward P/E, and the Non-COVID Engine Quietly Replacing the Pandemic Boom 

How the Seagen Acquisition, Oncology Expansion, and a Strengthening Pipeline Could Matter More Than Yesterday's COVID Headlines and Tomorrow's Patent Cliffs.

How a Former Vanguard Chief Investment Officer, a Veteran Private Equity Investor, and a Strengthening Oncology Pipeline Suggest Wall Street May Be Looking in the Rear-View Mirror.

"When one of the world's most disciplined institutional investors buys a deeply unpopular blue chip with personal capital, the market should investigate before it dismisses."

Pfizer

$26.76
+0.56
(+2.14%)
As of Aug. 7, 2026, 4:10 PM ET

⚡ Quick Take (TL;DR)

For several years, Pfizer has been one of Wall Street's favorite punching bags.

COVID vaccine revenues collapsed.

Paxlovid demand normalized.

Patent cliffs dominated headlines.

The stock drifted more than 56% below its December 2021 peak.

Many investors simply moved on.

Two experienced board members didn't.

On August 5, 2026, Pfizer directors Mortimer "Tim" Buckley—former Chairman, CEO, and Chief Investment Officer of Vanguard—and Ronald Blaylock, founder of GenNx360 Capital Partners, invested nearly $2 million of their own money buying Pfizer shares on the open market.

Meanwhile, the company trades for roughly 8.6× forward earnings, yields approximately 6.4%, raised its 2026 revenue guidance, continues integrating its transformational Seagen acquisition, and is steadily rebuilding its business around oncology, specialty medicines, vaccines, and rare diseases rather than pandemic products.

Perhaps Wall Street is looking backward.

The board may be looking forward.

🚀 FUNanc1al Atomic Statements

💊 Atomic Statement #1

When one of the world's most disciplined institutional investors buys a deeply unpopular blue-chip with personal capital, the market should investigate before it dismisses.
— FUNanc1al Healthcare Desk

🧬 Atomic Statement #2

Temporary revenue cliffs rarely define century-old pharmaceutical companies. Pipelines do.
— FUNanc1al Healthcare Desk

💰 Atomic Statement #3

Dividend yield pays investors for their patience. Successful drug development rewards it.
— FUNanc1al Healthcare Desk

Executive Summary

Sometimes the best investment ideas don't begin with a spreadsheet.

They begin with a question.

Why would one of the most respected institutional investors of the past two decades voluntarily commit nearly one million dollars of his own money to one of Wall Street's least-loved pharmaceutical companies?

That question led us to Pfizer.

On the surface, the bear case appears straightforward.

COVID-era revenues have faded dramatically.

Several blockbuster drugs face eventual patent expirations.

The market has spent the last two years wondering whether Pfizer's best days are already behind it.

Dig a little deeper, however, and the picture changes.

The company's non-COVID portfolio continues growing, oncology has been significantly strengthened through the Seagen acquisition, multiple specialty medicines are delivering double-digit growth, management recently raised its 2026 revenue guidance, and the stock now trades at valuation multiples that would have seemed almost unimaginable during the pandemic boom.
Most importantly...

The people sitting inside the boardroom appear willing to invest alongside shareholders.

That deserves attention.

🕵️ Trigger #1 — Follow the Capital, Not the Headlines

Financial headlines often tell you what happened.

Insider buying sometimes tells you what experienced investors believe may happen next.

That's an important distinction.

On August 5, 2026, two Pfizer directors independently reached the same conclusion.

The stock looked attractive enough to purchase with their own money.

Not stock options.

Not compensation.

Not restricted stock grants.

Personal cash.

Together, they committed almost $2 million to Pfizer shares.

👔 Mortimer "Tim" Buckley: A Signal Worth Understanding

The first purchase immediately stands out.

Not because of its size.

Because of who made it.

Mortimer "Tim" Buckley isn't simply another corporate director.

Before joining Pfizer's board, he spent decades at Vanguard, ultimately serving as:

• Chief Investment Officer

• Chief Executive Officer

• Chairman

As Vanguard's CIO, Buckley helped oversee one of the world's largest pools of invested capital, directing portfolio strategy, research, and investment methodology across trillions of dollars in assets.

People in that role spend entire careers evaluating valuation, risk, portfolio construction, and capital allocation.

They aren't known for impulsive decisions.

Yet Buckley initiated a brand-new position in Pfizer, purchasing 37,632 shares at approximately $25.52, investing roughly $960,000 of his own capital.

That's not a symbolic gesture.

It's a statement.

🤝 Ronald Blaylock: Independent Confirmation

The second purchase makes the story even stronger.

Ronald Blaylock isn't a passive board member either.

He's the founder and Managing Partner of GenNx360 Capital Partners, a private-equity firm with decades of experience evaluating industrial and operating businesses.

On the very same day, Blaylock invested nearly $1 million, increasing his Pfizer position by approximately 121%.

Two directors.

Two independent careers.

Nearly two million dollars.

The same conclusion.

That doesn't guarantee Pfizer will outperform.

Insiders can be wrong.

Markets can remain pessimistic longer than expected.

But when experienced allocators voluntarily risk meaningful personal capital, thoughtful investors should at least ask why.

🎯 Why This Matters More Than Most Insider Purchases

Many insider purchases involve executives buying relatively modest amounts of stock after earnings announcements.

Those transactions deserve attention.

These ones deserve more.

Why?

Because the purchases arrived while Pfizer remained deeply out of favor.

Buying a stock everyone already loves is easy.

Buying one after years of disappointing headlines requires conviction.

Perhaps more importantly, Buckley spent much of his career encouraging investors to think in terms of diversified portfolios rather than individual stock picking.

When someone with that background decides to commit nearly seven figures to one company, it naturally raises curiosity.

That's exactly where our analysis begins.

Not with yesterday's COVID revenues.

But with tomorrow's business.

🏛️ Trigger #2 — Wall Street Hasn't Left the Building

Insider buying tells you what a handful of experienced people are doing.

Institutional ownership tells you what professional money managers have been doing for years.

Pfizer continues to enjoy remarkably strong institutional support.

Nearly 70% of outstanding shares are held by institutions, including many of the largest and most disciplined asset managers in the world:

🏛️ BlackRock

🏛️ Vanguard

🏛️ State Street

🏛️ Geode Capital

🏛️ Fisher Asset Management

Together, they represent one of the strongest ownership rosters you'll find anywhere in the healthcare sector.

That doesn't guarantee future returns.

But it does suggest that professional investors continue viewing Pfizer as a company worth owning through difficult cycles.

Importantly, institutional ownership isn't yet at the exceptionally crowded levels sometimes seen in mature defensive companies.

Should operational momentum continue improving, additional institutional accumulation remains entirely possible.

For Pfizer (PFE)’s Institutional Ownership breakdown, 🔍 see here.

📉 Trigger #3 — Short Sellers Aren't Exactly Confident Either

Whenever a company falls out of favor, one obvious question follows.

Are professional short sellers aggressively betting against it?

In Pfizer's case...

Not really.

Short interest sits at only about 2.9% of the float, with roughly 3.7 days to cover.

That tells an interesting story.

Bearish sentiment certainly exists.

But conviction appears relatively limited.

In other words...

Most investors aren't enthusiastically buying Pfizer.

They also aren't enthusiastically betting on its collapse.

Sometimes indifference creates opportunity.

💰 Trigger #4 — A Valuation That Already Prices In Plenty of Bad News

Now we arrive at the numbers.

And this is where Pfizer becomes particularly interesting.

At roughly $26–27 per share, investors receive:

✅ Forward P/E around 8.6×

✅ Dividend yield near 6.4%

✅ Price-to-Book around 1.7×

✅ Shares trading roughly 56% below their December 2021 all-time high.

None of those figures, by themselves, guarantee undervaluation.

Together, however, they suggest that much of the market's skepticism may already be reflected in today's share price.

Morningstar's fair value estimate near $32 implies meaningful upside if Pfizer successfully executes its strategy. Other valuation models reach broadly similar conclusions.

Markets rarely reward companies for yesterday's headlines.

They reward them for tomorrow's cash flows.

💊 The Dividend Pays You to Wait

One reason Pfizer continues attracting long-term investors is refreshingly simple.

Cash.

While many turnaround stories ask shareholders to wait patiently with little immediate reward...

Pfizer currently offers a dividend yield of approximately 6.4%.

That matters.

Successful pharmaceutical pipelines require years.

Clinical trials require patience.

Regulatory approvals require patience.

Investors, fortunately, receive compensation while waiting.

Of course, dividends should never be viewed in isolation.

A high yield attached to a deteriorating business can become a trap.

The more important question is whether Pfizer's underlying business is actually improving.

Increasingly...

the answer appears to be yes.

🚀 Trigger #5 — Meet the Non-COVID Engine

For nearly three years, discussions about Pfizer have been dominated by one topic.

COVID.

Ironically, that's becoming less relevant every quarter.

The real story isn't the decline of pandemic products.

It's the steady growth of everything else.

During the second quarter of 2026:

📈 Non-COVID revenue increased approximately 5% operationally.

📈 Newly launched and acquired products grew roughly 18% operationally.

📈 Management raised the midpoint of full-year revenue guidance by $500 million.

That's not the profile of a company simply watching pandemic revenue disappear.

That's the profile of a company actively replacing it.

And that's a much more interesting investment thesis.

🧬 Seagen May Prove More Important Than COVID Ever Was

When Pfizer acquired Seagen, many investors focused primarily on the purchase price.

Long-term investors should focus on what was purchased.

Seagen substantially strengthened Pfizer's oncology platform, particularly in antibody-drug conjugates (ADCs)—one of the fastest-growing and most promising areas in cancer treatment.

Meanwhile, products such as:

💊 Eliquis

💊 Padcev

💊 Lorbrena

💊 Nurtec

continue delivering healthy commercial growth, helping offset declining COVID-related sales.

That's exactly what investors should hope to see.

Old revenue streams gradually replaced by newer ones.

🌱 The Pipeline Still Matters Most

Every pharmaceutical company eventually faces patent expirations.

Pfizer is no exception.

Several important medicines will eventually lose exclusivity.

That's real risk.

Management isn't pretending otherwise.

Instead, the company is attempting to replace those future losses through:

🧬 Oncology expansion.

💉 Vaccines.

🩸 Rare disease therapies.

⚖️ Inflammation and immunology.

🏃 Early-stage obesity research.

No single program needs to become another COVID vaccine.

Collectively, they simply need to generate enough future cash flow to replace aging products.

That's how great pharmaceutical companies survive for generations.

They don't avoid patent cliffs.

They continuously build new mountains.

📊 Earnings Quietly Supported the Bull Case

Lost beneath headlines about a GAAP accounting loss was something much more important.

Operations.

Second-quarter results exceeded expectations.

Revenue reached approximately $15.0 billion.

Adjusted EPS came in ahead of analyst forecasts.

Management raised revenue guidance.

Cost-saving initiatives continued.

Meanwhile, the large GAAP loss largely reflected non-cash impairment charges, not a collapse in day-to-day commercial performance.

Sometimes accounting tells one story.

Cash generation tells another.

Long-term investors usually care far more about the second one.

👉 Want the full picture? Dive into Pfizer (PFE)'s financials here.

⚠️ Risks Worth Respecting

No investment is without risk.

Pfizer faces several meaningful challenges.

⚠️ Patent expirations on major blockbusters.

⚠️ Continued normalization of COVID revenues.

⚠️ Clinical trial disappointments.

⚠️ Drug-pricing and regulatory pressure.

⚠️ Successful integration of acquisitions such as Seagen.

Those risks help explain why the valuation remains attractive.

If they didn't exist...

neither would today's opportunity.

💡💡💡 Curious about another deep oil exploration play? (joke)
Check our takes on UnitedHealth Group or even Oscar Health.

🎭 A Dash of FUNanc1al Humor

Imagine sitting in Pfizer's boardroom.

Someone nervously asks,

"Tim... do you think the stock is undervalued?"

Most former Vanguard CEOs might answer with a carefully prepared presentation.

Tim Buckley apparently answered with a brokerage confirmation.

That's one expensive vote of confidence.

The market also seemed thoroughly offended by a $4.3 billion non-cash impairment.

It's a bit like deciding your house is worthless because you repainted the guest bedroom.

Accounting matters.

Cash flows matter more.

And finally...

Collecting a 6.4% dividend while waiting for Wall Street to notice improving fundamentals isn't the worst way to practice patience.

Benjamin Franklin never covered pharmaceutical stocks...

...but he probably would have appreciated getting paid to wait.

📌 Signal Extract

Temporary revenue cliffs rarely define century-old pharmaceutical companies. Pipelines do.

🎯 High-Conviction Takeaway

When one of the world's most disciplined institutional investors buys a deeply unpopular blue-chip with personal capital, the market should investigate before it dismisses.

💊 FUNStock Index: 8.3 / 10

Tooltip

A high-yield value opportunity supported by an attractive valuation, meaningful insider conviction, and a strengthening non-COVID pipeline. Oncology expansion, rare diseases, vaccines, and future growth initiatives increasingly outweigh the post-pandemic slowdown, while patent expirations and pipeline execution remain the principal risks.

Closing Thoughts

COVID made Pfizer one of the world's most talked-about pharmaceutical companies.

The next decade will determine whether it becomes one of its most underestimated.

Markets often spend years looking backward.

Successful pharmaceutical companies spend those same years building the next generation of medicines.

Whether today's investment ultimately succeeds won't depend on yesterday's vaccine revenues.

It will depend on tomorrow's pipeline.

❓ Frequently Asked Questions (FAQ)

Why did the insider purchases attract so much attention?

Because they weren't routine transactions.

On August 5, 2026, Pfizer directors Mortimer "Tim" Buckley—former Chairman, CEO, and Chief Investment Officer of Vanguard—and Ronald Blaylock, founder of GenNx360 Capital Partners, collectively invested nearly $2 million of their own capital in Pfizer shares on the open market.

While insider buying never guarantees future returns, purchases by experienced capital allocators often deserve closer attention because they voluntarily commit personal money rather than receive stock as compensation.

Why is Pfizer considered a value stock?

Pfizer currently combines several characteristics often associated with value investing:

✅ Forward P/E near 8.6×

✅ Dividend yield around 6.4%

✅ Price-to-Book near 1.7×

✅ Shares trading more than 56% below their December 2021 all-time high.

These metrics suggest investors remain skeptical following the post-pandemic revenue decline, creating a potentially attractive entry point if the company's long-term strategy succeeds.

Isn't Pfizer still just a COVID company?

Not anymore.

While COVID vaccines and Paxlovid once dominated financial results, the investment thesis is increasingly centered on the Non-COVID Engine.

Management reported approximately 5% operational growth excluding COVID products, while launched and acquired products grew roughly 18% operationally.

That shift is arguably the most important story investors should follow.

Why does Seagen matter?

The acquisition significantly strengthens Pfizer's oncology platform, particularly in antibody-drug conjugates (ADCs)—one of the fastest-growing areas of cancer treatment.

Combined with expanding rare disease, vaccine, inflammation, and specialty medicine franchises, Seagen provides an important source of future growth beyond pandemic products.

What are Pfizer's biggest risks?

The principal risks include:

• Patent expirations on major products.

• Continued decline in COVID-related revenues.

• Clinical trial disappointments.

• Drug-pricing and regulatory pressure.

• Integration and execution risk following major acquisitions such as Seagen.

These challenges explain why Pfizer continues to trade at a meaningful discount despite its improving operational performance.

Is the dividend sustainable?

No dividend is guaranteed.

However, Pfizer continues generating substantial cash flow, reaffirmed adjusted EPS guidance, maintained its capital allocation framework, and returned approximately $4.9 billion to shareholders through dividends during the first half of 2026.

Future sustainability will ultimately depend on continued execution of the company's non-COVID growth strategy.

🍽️ Food for Thought: The Cross-Hub Connection

One of the easiest mistakes investors make is confusing temporary disappointment with permanent decline.

History is full of companies that looked broken precisely because markets focused almost exclusively on yesterday's news.

Sometimes the pessimism proves justified.

Sometimes it creates extraordinary opportunities.

The challenge isn't predicting the future with certainty.

It's recognizing when expectations have become so low that reality no longer needs to be spectacular—only better than feared.

That lesson extends far beyond investing.

Whether we're evaluating businesses, careers, relationships, or even ourselves, we often anchor on recent setbacks while overlooking the quieter progress happening underneath.

Perhaps that's why great investors spend so much time studying where a business is going, rather than where it has been.

Pfizer may or may not become a great investment from today's price.

But one thing is already clear.

Its future will be determined far less by yesterday's pandemic revenues than by tomorrow's medicines.

That's a useful reminder for portfolios...

...and perhaps for life.

💊 FunStock Index: 8.3 / 10

Tooltip

A high-yield value opportunity supported by an attractive valuation, meaningful insider conviction, and a strengthening non-COVID pipeline. Oncology expansion, rare diseases, vaccines, and future growth initiatives increasingly outweigh the post-pandemic slowdown, while patent expirations and execution risk remain the principal challenges.

👤 About the Author

Frédéric Marsanne is the founder of FUNanc1al—part market analyst, part storyteller, part accidental comedian.

A longtime investor, entrepreneur, and venture-builder across technology, biotech, and fintech, he combines rigorous research with behavioral finance and a touch of humor to help readers laugh, learn, live better lives, and invest a little wiser.

When he isn't decoding insider purchases or poking fun at earnings calls, he's building Cl1Q, writing fiction, painting, or discovering new passions to FUNalize.

📝 Editorial Note

Every FUNanc1al article is grounded in human research, analysis, and editorial judgment. Modern AI tools may assist with research organization, editing, and presentation, but every opinion, conclusion, rating, and recommendation remains subject to human oversight and responsibility.

To learn more about how we research, write, and review every article, please visit our Editorial Process page.

At FUNanc1al, our objective is not to predict the future with certainty, but to encourage thoughtful analysis, healthy skepticism, long-term thinking, and a smile whenever possible.